Announced exclusive license agreement with Jazz Pharmaceuticals to develop and commercialize zanidatamab, Zymeworks’ lead clinical candidate, for total potential payments of up to $1.76 billion , plus royalties on net sales Hosted Early Research and Development day highlighting progress in  Continue Reading

VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Oct. 7, 2022-- Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce that the Company’s securityholders have approved its plan  Continue Reading

Zanidatamab zovodotin (ZW49) accepted for oral presentation of Phase 1 clinical data at European Society for Medical Oncology (ESMO) Congress in September Announced Early Research and Development (eR&D) day presentation and webcast for October 20 th , 2022 with focus on TOPO1i antibody-drug  Continue Reading

Last patient enrolled ahead of expectations in pivotal trial evaluating zanidatamab as monotherapy in 2L biliary tract cancers (BTC) Two zanidatamab data presentations at ASCO in June: 1L breast cancer and 1L gastroesophageal adenocarcinoma ( GEA ) Presented topoisomerase 1 inhibitor (TOPO1i)  Continue Reading

Enrollment on track for both pivotal trials of zanidatamab in 1L gastroesophageal adenocarcinoma (GEA) and 2L biliary tract cancer (BTC). Announced submission of abstracts for upcoming clinical data for the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting.  Continue Reading